Journal ArticleDOI
Neuroblastoma: Biology, Prognosis, and Treatment
TLDR
This article summarizes the understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure.Abstract:
Neuroblastoma, a neoplasm of the sympathetic nervous system, is the second most common extracranial malignant tumor of childhood and the most common solid tumor of infancy. Neuroblastoma is a heterogeneous malignancy with prognosis ranging from near uniform survival to high risk for fatal demise. Neuroblastoma serves as a paradigm for the prognostic utility of biologic and clinical data and the potential to tailor therapy for patient cohorts at low, intermediate, and high risk for recurrence. This article summarizes our understanding of neuroblastoma biology and prognostic features and discusses their impact on current and proposed risk stratification schemas, risk-based therapeutic approaches, and the development of novel therapies for patients at high risk for failure.read more
Citations
More filters
Journal ArticleDOI
The Hox genes and their roles in oncogenesis
Nilay Shah,Saraswati Sukumar +1 more
TL;DR: Hox genes, a highly conserved subgroup of the homeobox superfamily, have crucial roles in development, regulating numerous processes including apoptosis, receptor signalling, differentiation, motility and angiogenesis, and could be important in diagnosis and therapy.
Journal ArticleDOI
Neuroblastoma
TL;DR: Neuroblastoma is a type of cancer that most often affects children and can spread to other parts of the body such as the bones, liver, or skin.
Journal ArticleDOI
Neuroblastoma: Paradigm for Precision Medicine
Meredith S. Irwin,Julie R. Park +1 more
TL;DR: Current clinical trials have continued to reduce therapy for patients with non-high-risk NB, including the most favorable subsets who are often followed with observation approaches, and high-risk patients are treated aggressively with chemotherapy, radiation, surgery, and myeloablative and immunotherapies.
Journal ArticleDOI
Mutational dynamics between primary and relapse neuroblastomas
Alexander Schramm,Johannes Köster,Johannes Köster,Yassen Assenov,Kristina Althoff,Martin Peifer,E Mahlow,Andrea Odersky,Daniela Beisser,Corinna Ernst,Anton G. Henssen,Anton G. Henssen,Anton G. Henssen,Harald Stephan,Christopher Schröder,Lukas C. Heukamp,Anne Engesser,Yvonne Kahlert,Jessica Theissen,Barbara Hero,Frederik Roels,Janine Altmüller,Peter Nürnberg,Kathy Astrahantseff,Christian Gloeckner,Katleen De Preter,Christoph Plass,Sangkyun Lee,Holger N. Lode,Kai Oliver Henrich,Moritz Gartlgruber,Frank Speleman,Peter Schmezer,Frank Westermann,Sven Rahmann,Sven Rahmann,Matthias Fischer,Angelika Eggert,Angelika Eggert,Johannes H. Schulte,Johannes H. Schulte,Johannes H. Schulte +41 more
TL;DR: The mutational burden significantly increased in relapsing tumors, accompanied by altered mutational signatures and reduced subclonal heterogeneity and global allele frequencies at relapse indicated clonal mutation selection during disease progression.
Journal ArticleDOI
Functional genomics identifies therapeutic targets for MYC-driven cancer
Masafumi Toyoshima,Heather L. Howie,Maki Imakura,Ryan M. Walsh,James Annis,Aaron N. Chang,Jason Frazier,B. Nelson Chau,Andrey Loboda,Peter S. Linsley,Michele A. Cleary,Julie R. Park,Carla Grandori +12 more
TL;DR: Through a functional genomics approach, pathways essential in the context of oncogenic MYC but not to normal cells were identified, revealing a rich therapeutic space linked to a previously “undruggable” oncogene.
References
More filters
Journal ArticleDOI
Identification of human brain tumour initiating cells
Sheila K. Singh,Cynthia Hawkins,Ian D. Clarke,Jeremy A. Squire,Jane Bayani,Takuichiro Hide,R. Mark Henkelman,Michael D. Cusimano,Peter B. Dirks +8 more
TL;DR: The development of a xenograft assay that identified human brain tumour initiating cells that initiate tumours in vivo gives strong support for the CSC hypothesis as the basis for many solid tumours, and establishes a previously unidentified cellular target for more effective cancer therapies.
Journal ArticleDOI
A human colon cancer cell capable of initiating tumour growth in immunodeficient mice
TL;DR: The identification of colon cancer stem cells that are distinct from the bulk tumour cells provides strong support for the hierarchical organization of human colon cancer, and their existence suggests that for therapeutic strategies to be effective, they must target the cancer stem Cells.
Book
Pathology of Tumours of the Nervous System
TL;DR: Pathology of Tumours of the Nervous System, by Dorothy S. Russell, Sc.D.
Journal ArticleDOI
Neuroblastoma: biological insights into a clinical enigma.
TL;DR: Recent advances in understanding the biology and genetics of neuroblastomas have allowed classification into low-, intermediate- and high-risk groups, which allows the most appropriate intensity of therapy to be selected — from observation alone to aggressive, multimodality therapy.
Journal ArticleDOI
Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.
Garrett M. Brodeur,J Pritchard,Frank Berthold,N L Carlsen,Victoria Castel,R P Castelberry,B. De Bernardi,Audrey E. Evans,Favrot M,F Hedborg +9 more
TL;DR: The International Neuroblastoma Staging System (INSS) as mentioned in this paper was proposed to establish an internationally accepted staging system for neuroblastoma, as well as consistent criteria for confirming the diagnosis and determining response to therapy.